MARKET

ANGO

ANGO

AngioDynamics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

24.70
-0.61
-2.41%
Opening 09:40 09/20 EDT
OPEN
24.83
PREV CLOSE
25.31
HIGH
24.85
LOW
24.59
VOLUME
5.66K
TURNOVER
--
52 WEEK HIGH
30.25
52 WEEK LOW
9.47
MARKET CAP
949.57M
P/E (TTM)
-30.0889
1D
5D
1M
3M
1Y
5Y
Oppenheimer Initiates Coverage On AngioDynamics with Perform Rating
Oppenheimer analyst Steven Lichtman initiates coverage on AngioDynamics (NASDAQ:ANGO) with a Perform rating.
Benzinga · 08/20 12:36
--Oppenheimer Initiates Coverage on AngioDynamics With Perform Rating
MT Newswires · 08/20 10:13
Insider Trends: Insider at AngioDynamics Acquires Stock Via Conversion of Option/Derivative Security Sells Portion to Pay Tax, Buy Trend Intact
MT Newswires · 08/17 06:58
Why Is AngioDynamics (ANGO) Up 2.3% Since Last Earnings Report?
Zacks.com · 08/12 15:30
AngioDynamics to Present at the Canaccord Genuity Virtual Growth Conference
LATHAM, N.Y., July 29, 2021--AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Exec...
Business Wire · 07/29 20:01
Insider Trends: AngioDynamics Insider Gets Shares Award Makes Tax Sale with Portion, Easing 90-Day Buy Trend
MT Newswires · 07/23 18:49
Canaccord Genuity Maintains Hold on AngioDynamics, Raises Price Target to $28
Canaccord Genuity maintains AngioDynamics (NASDAQ:ANGO) with a Hold and raises the price target from $24 to $28.
Benzinga · 07/14 14:23
AngioDynamics (ANGO) Q4 Earnings Match Estimates, Revenues Top
AngioDynamics (ANGO) registers strong revenue growth across all its GBUs in fiscal 2021 Q4.
Zacks · 07/14 13:21
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ANGO. Analyze the recent business situations of AngioDynamics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ANGO stock price target is 30.00 with a high estimate of 32.00 and a low estimate of 28.00.
EPS
Institutional Holdings
Institutions: 260
Institutional Holdings: 39.91M
% Owned: 103.80%
Shares Outstanding: 38.44M
TypeInstitutionsShares
Increased
48
2.26M
New
27
1.01M
Decreased
65
2.34M
Sold Out
10
564.98K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-1.06%
Healthcare Equipment & Supplies
-1.05%
Key Executives
Chairman/Independent Director
Howard Donnelly
President/Chief Executive Officer/Director
James Clemmer
Chief Financial Officer/Executive Vice President/IR Contact Officer
Stephen Trowbridge
Senior Vice President/General Counsel/Secretary
Richard Rosenzweig
Senior Vice President/General Manager
Brent Boucher
Senior Vice President/General Manager
Chad Campbell
Senior Vice President/General Manager
Scott Centea
Senior Vice President/Director of Human Resources
Marna Bronfen-Moore
Senior Vice President
Benjamin Davis
Senior Vice President
David Helsel
Senior Vice President
Warren Nighan
Senior Vice President
Kim Seabury
Other
Juan Serna
Independent Director
Eileen Auen
Independent Director
Wesley Johnson
Independent Director
Karen Licitra
Independent Director
Dennis Meteny
Independent Director
Jan Reed
Independent Director
Michael Tarnoff
No Data
About ANGO
AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Vascular Interventions & Therapies, Vascular Access and Oncology. The Company's Vascular Interventions & Therapies products include Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines. Through its subsidiary, Eximo Medical, Ltd., the Company operates 355 nanometers (nm) wavelength laser-technology platform.

Webull offers kinds of AngioDynamics, Inc. stock information, including NASDAQ:ANGO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANGO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ANGO stock methods without spending real money on the virtual paper trading platform.